A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Recruiting

Phase 1

Phase 2

RepotrectinibA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Sponsor:

Turning Point Therapeutics, Inc.

Code:

NCT04094610

Conditions

Locally Advanced Solid Tumors

Metastatic Solid Tumors

Lymphoma

Primary CNS Tumors

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Interventions

Oral repotrectinib (TPX-0005)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-06. This information was provided to ClinicalTrials.gov by Turning Point Therapeutics, Inc. on 2025-11-04.